GLP-1 Medications and Birth Control: What Changes and When

The two medications are not the same on this, which is the single most important thing to know and the thing most people get wrong.

If you take an oral contraceptive and you are on tirzepatide, there is specific labeled advice that applies to you, and the timing of it is not what most people assume.

What the tirzepatide label actually says

The Mounjaro prescribing information, in section 8.3, advises patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or to add a barrier method of contraception, for four weeks after starting and for four weeks after each dose escalation.

Read that last part again, because it is the part that catches people out.

It is not a one-time window at the start. It applies again after every dose increase. A standard titration involves several increases over several months, and each one opens another four-week window. Someone who took the advice seriously in month one and then stopped thinking about it has been uncovered through every step since.

The mechanism is in the label itself: tirzepatide can reduce the efficacy of oral hormonal contraceptives because it delays gastric emptying, and that delay is largest after the first dose and diminishes over time. Each increase is a new first dose at that level, which is why the window reopens rather than closing for good.

What counts as a non-oral method is a conversation for your prescriber or pharmacist rather than something to decide from an article, because it depends on what you are currently using and why. The two routes the label describes are switching to a non-oral method or keeping your pill and adding a barrier method on top.

Injectable semaglutide is a different situation

The Wegovy label carries no equivalent backup-contraception advice, and the reason is worth knowing, because it is not that the question was left open.

The label’s drug interaction section reports that no clinically significant differences in semaglutide pharmacokinetics were seen alongside a list of medications that includes ethinyl estradiol and levonorgestrel. Those are the two hormones in many combined oral contraceptives. In other words, the interaction was studied and did not turn up a clinically relevant effect.

That is a positive finding rather than a gap, and it is a meaningful difference between the two medications. Tirzepatide delays stomach emptying enough that the label attaches an instruction. Injectable semaglutide was evaluated against the same hormones and did not.

What that does not settle is your own situation. If you have been vomiting heavily, the general rule about oral medications below still applies to you, whichever product you take. And oral semaglutide is a different product again, with different absorption behavior, so a conclusion about an injection does not transfer to a tablet. Ask about what you actually take.

Oral semaglutide is a different product again and has its own considerations. Do not assume a rule that applies to an injection applies to a tablet.

The situation that applies to everyone

Separate from any labeled interaction, there is a practical one.

Severe vomiting or diarrhea can reduce the absorption of any oral medication, including contraceptives. GLP-1 medications cause both in some people, particularly in the days after starting or increasing a dose.

So if you have been genuinely unwell after a dose, that is a reason to check what your contraceptive’s own instructions say about vomiting and missed absorption, and to ask a pharmacist. This is not a GLP-1 specific rule. It is a rule about oral contraceptives that a GLP-1 can put you in the path of.

Consider this scenario: someone on tirzepatide follows the four-week advice carefully when she starts in January. She moves up a dose in March, again in May, and again in July, and each time she thinks of the escalation as a dose change rather than as a contraception event. She has spent twelve weeks of the year in windows the label describes, without knowing any of them were open. Nothing in her experience of the medication would have told her.

If you have already been through escalations without backup

This is common, and the useful response is a phone call rather than alarm.

Talk to your prescriber or a pharmacist. Tell them which medication and dose you are on, when your increases happened, what contraceptive you take, and whether you have had vomiting or diarrhea around any of those dates. They can tell you what, if anything, is worth doing now, and what to put in place for the next increase.

Going forward, the practical fix is to treat every planned dose increase as a scheduled event with two parts: the dose, and the four weeks of backup. Our guides on dose escalation and when to increase your tirzepatide dose cover the schedule side, and the contraception window rides alongside it.

If you are planning a pregnancy

This is a different question and the answer is not the same for every product.

The Wegovy label advises discontinuing at least two months before a planned pregnancy, to account for how long the medication stays in the body. It also advises discontinuing when pregnancy is recognized. The Mounjaro label states the medication should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

What that means practically is that stopping is not something to do the month you start trying. It needs planning with your prescriber, with enough lead time, and the interval depends on which product you take. Raise it early rather than when you are ready.

What to ask, and who to ask

Your prescriber and your pharmacist are both useful here and they know slightly different things. Worth asking:

• Does my specific medication carry contraception advice, and does it apply after every dose increase
• Given my contraceptive, is switching methods or adding a barrier method the better route for me
• What should I do if I vomit in the days after a dose
• If I want to plan a pregnancy, how far ahead do I need to stop

Bring the actual product name to that conversation rather than the drug class, because the answers differ between them. Our guide on how tirzepatide and semaglutide compare covers the broader differences between the two.

The short version

Tirzepatide carries labeled contraception advice for oral contraceptive users: switch to a non-oral method or add a barrier method, for four weeks after starting and for four weeks after each dose increase. The repeat-after-every-increase part is what people miss. Injectable semaglutide does not carry that advice because the interaction was studied and no clinically relevant effect was found, which is a genuine difference between the two. Severe vomiting can affect oral contraceptive absorption whatever you take. And if pregnancy is in your plans, the stopping interval needs lead time and depends on the product.

If you want a provider who flags this alongside each dose change rather than leaving it in the label, TrimRx includes ongoing provider access alongside treatment.

This information is for educational purposes and is not medical advice. Consult with a healthcare provider before starting any medication. Individual results may vary.